Tuesday, July 17, 2018
News: Page (1) of 1 - 03/08/12 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
FDA links once-promising pain drugs to bone decay
FDA says once-promising pain medications increase rates of bone decay and joint failure
By The Associated Press

WASHINGTON (AP) ' Some of the world's largest drugmakers will face an uphill battle next week in their bid to revive a class of experimental arthritis drugs that have been sidelined by safety concerns for nearly two years.

The Food and Drug Administration says there is a clear association between the nerve-blocking medications and incidents of joint failure that led the agency to halt studies of the drugs in 2010.

However, the agency also notes that those side effects were less common when the drugs were used at lower doses, potentially leaving the door open for future use. The agency released its safety analysis ahead of a public meeting.

On Monday Pfizer, Johnson & Johnson and Regeneron will make their case to continue studies of the drugs, with precautions to protect patients.

Page: 1


Our Privacy Policy --- About The U.S. Daily News - Contact Us - Advertise With Us - Privacy Guidelines